Cost comparisons of five leading brands of the Antiplatelet drug, Clopidogrel, available in an Indian town
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20193134Keywords:
Antiplatelet drugs, Clopidogrel seventy five milligram, Pharmaco economics, Yearly costAbstract
Background: Antiplatelet drugs need to be prescribed lifelong, for most of the selected patients, once started. Price disparity can lead to large financial stress on the patients, especially when cost related aspects are not paid heed to by the prescribing physician. This study was conducted to compare the cost, to the patient, of five most commonly prescribed preparations of different brands of Clopidogrel seventy five milligram, in Kolhapur city.
Methods: The present study was undertaken during February 2019 to June 2019. Authors purchased a strip of 10 tablets each of the five leading brands of Clopidogrel seventy five milligram. The prices of the strip of 10 tablets of each of the five chosen brands were compared. Finally, the yearly cost of each of these five different preparations, was compared directly as well as using percentages. The data was collected, analyzed and presented in tabular forms and figures.
Results: The data of the cost of five different brands of a single antiplatelet drug, Clopidogrel seventy five milligram shows that the annual cost of the costliest among the five brands of this drug is almost three times that of the cheapest brand, or in other words almost 300 percent that of the cheapest brand.
Conclusions: The cost differences between the five brands were not negligible. India, with a major part of the population being very sensitive to the cost of medications, the prescribing physician must select the preparation wisely. The most costly preparation of Clopidogrel can significantly add to the the financial stress on the patient’s yearly expenditure. Thus, Pharmaco economic considerations must take a front seat while making a decision to prescribe medicines, especially in a country like India.
Metrics
References
Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol. 2006;147(suppl 1):S241-51.
Banerji A. Review of asia-pacific's healthcare systems with emphasis on the role of generic pharmaceuticals. Academy of Health Care Management J. 2013;9(1/2):53A.
Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, et al. Prices & availability of common medicines at six sites in India using a standard methodology. Ind J Med Res. 2007;125(5):645-54.
The Drug Price Control Order, 2013. National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India Available at: http://www.nppaindia.nic.in/en/drug-policies/drugs-price-control-order-2013. Accessed 5 May 2019.
Koenig-Oberhuber V, Filipovic M. New antiplatelet drugs and new oral anticoagulants. BJA: Br J Anaesthesia. 2016;117(suppl_2):ii74-84.
Sakthivel Selvaraj. How effective is India's drug price control regime?. Harvard T. H. Chan School of Public Health. Available at: https:// www.hsph.harvard.edu/takemi/files/2012/10/RP256.pdf. Accessed 5 May 2019.
Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines? Study of the impact of drug price control order on sales volume of drugs in India. IIMA. 2014;34(4):64-5.
DPCO Impact: Pharma cos growth suffers for drugs under price ceiling/ Business Standard News, 2013. Available at: https://www.business-standard.com/article/companies/dpco-impact-pharma-cos-growth-suffers-for-drugs-under-price-ceiling-113081800677_1.html. Accessed 18 Auguest 2013.
Vernon JA, Golec JH, Hughen WK. The economics of pharmaceutical price regulation and importation: refocusing the debate. Am J Law & Medi. 2006;32(2-3):175-92.
Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet. 2011;377(9764):505-15.
Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Direct Assoc. 2012;13(9):818-e11.
